Quarterly ResultMay 15, 2026, 05:22 PM
TuHURA Biosciences Q1 Net Loss Widens to $7.54M
AI Summary
TuHURA Biosciences reported a net loss of $7.54 million for the first quarter of 2026, an increase from $6.66 million in the prior year. Despite the wider loss, the company's cash and cash equivalents significantly increased to $6.30 million, driven by $7.50 million in proceeds from common stock issuance. The company anticipates its current capital resources will fund operations until the end of 2028.
Key Highlights
- Net loss for Q1 2026 was $7.54 million, up 13.09% from $6.66 million in Q1 2025.
- Cash and cash equivalents increased to $6.30 million as of March 31, 2026, from $3.62 million at December 31, 2025.
- Research and development expenses rose 14.20% to $5.23 million in Q1 2026.
- General and administrative expenses increased 13.94% to $2.30 million in Q1 2026.
- Net loss per share improved to $(0.13) in Q1 2026 from $(0.15) in Q1 2025.
- Net cash used in operating activities improved to $(4.41) million in Q1 2026 from $(4.74) million in Q1 2025.
- Proceeds from common stock issuance totaled $7.50 million in Q1 2026.
- Company expects existing capital to fund operations into the end of 2028.
Price Impact
More from HURA